Infectious Disease Therapeutics Market to Witness Many Strategic Alliances During 2019 to 2026: Industry Analysis by Size, Share, Growth, Trends, Demand, Business Opportunities and Challenges

Global Infectious Disease Therapeutics Market – Insights

Infectious diseases are transmissible or communicable diseases caused by various organisms such as viruses, viroids, bacteria, nematodes such as parasitic roundworms and pinworms, arthropods such as ticks, mites, fleas, and lice, fungi such as ringworm, and other macroparasites such as tapeworms and other helminths. Use of advanced diagnostics and therapies along with increasing focus on hygiene and vaccination has minimized fatalities due to infectious diseases. However, mutating virus and bacteria may still pose a threat of new infectious diseases.

*The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1658

Increasing incidence of infectious diseases to augment growth of the global infectious disease therapeutics market

High prevalence of infectious diseases is expected to boost growth of the global infectious disease therapeutics market. For instance, according to the National Ambulatory Medical Care Survey: 2015 data findings, 16.8 million visits to physician offices for infectious and parasitic diseases were registered in the U.S. According to the same source, since September 2012, around 2,143 laboratory-confirmed cases of infection with MERS-CoV were recorded. According to the World Health Organization (WHO), GISRS (Global Influenza Surveillance and Response System) laboratories, from April 2, 2018 to April 15, 2018, tested over 137,071 specimens from various National Influenza centers (NIC) and other national influenza laboratories of 113 countries. Among these collected specimens, around 21,639 were positive for influenza viruses, wherein 12,034 (55.6%) were classified as influenza A and 9,605 (44.4%) as influenza B. According to the Centers for Disease Control and Prevention (CDC), around 5,251 deaths due to influenza infection were registered in the U.S. in 2015. According to the WHO, in 2015, around 32,000 estimated deaths from tuberculosis (TB) and around 3, 23,000 new cases of TB cases were registered in Europe. According to the data published in European Centre for Disease Prevention and Control (ECDC), in February 2018, around 44,000 deaths are registered annually from respiratory diseases associated with seasonal influenza in Europe, out of around 6,50,000 global deaths, annually.

Moreover, increasing awareness regarding early diagnosis of infectious diseases and R&D of new therapies for the treatment of these diseases is also expected to boost growth of the market. Continuous development in diagnostics facilitates early and rapid diagnosis of various infectious diseases. Rapid diagnosis of infectious diseases involves use of advanced technologies such as lateral flow, agglutination assays, and solid phase with portable handheld devices to enhance point-of-care (PoC) treatment. Therefore, increasing development in PoC treatment is expected to boost growth of the market over the forecast period. For instance, in 2014, Becton, Dickinson, and Company offered BD FACSPresto a PoC system for the treatment of HIV/AIDS. It offers percentage results of CD4 T lymphocytes and hemoglobin concentration. Moreover, in January 2017, Infectious Disease Research Institute (IDRI) developed a fusion antigen, which is used as a part of diagnostic test manufactured by InBios International, Inc. for Chagas disease.

Increasing funding for R&D in infectious diseases from various organizations is also expected to boost growth of the global infectious disease therapeutics market. For instance, in November 2016, QuantuMDx Group received funding from Bill & Melinda Gates Foundation to develop and test company’s CAPTURE-XT pathogen concentration technology and Q-POC molecular diagnostic platform for rapid low cost detection of tuberculosis. In January 2018, University of Glasgow-led project received US$ 1.85 million funding, which is a part of Global Challenges Research Fund (GCRF). This project will develop new tests for parasitic diseases and rapid testing in remote locations to help enable rapid diagnosis and rapid treatment of infectious diseases.

Special Requirements?
We value your investment and offer customization as per your requirements.

Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/1658

Lack of reimbursement for certain infectious diseases to hinder growth of the market

Lack of reimbursement for certain infectious diseases in selected countries and low awareness and low adoption of treatments is expected to hinder growth of the global infectious disease therapeutics market over the forecast period. For instance, the prevalence of infectious diseases in emerging regions of Africa and Asia is high. However, adoption of treatment for these diseases is low. According to AVERT, a global HIV and AIDS charity organization based in U.K., in 2015, 6.5 million individuals were infected with HIV in the West and Central African region and around 28% of the HIV infected people were accessing antiretroviral therapy. Furthermore, increasing availability of counterfeit drugs in Asia Pacific is also expected to hinder the market growth.

North America to account for the largest market share over the forecast period

North America is expected to account for the largest market share in the global infectious disease therapeutics market over the forecast period, followed by Europe. This is attributed to factors such as increasing R&D of new therapies for infectious diseases and high prevalence and awareness of these diseases in the region. For instance, according to the Centers for Disease Control and Prevention (CDC), the U.S. reported around 26,203 cases of Lyme disease between 2006 and 2016.

Asia Pacific is expected to witness the fastest growth in the global infectious disease therapeutics market over the forecast period. This is attributed to increasing launch of effective and raid diagnostic tests in the region. For instance, in March 2013, Qiagen N.V. launched its careHPV test in China. CareHPV is a molecular diagnostic test designed to screen for high risk human papillomavirus (HPV) at low-resource settings such as areas lacking electricity, water or laboratories. Qiagen also gained the approval from China’s State Food and Drug Administration (SFDA) for the careHPV in 2012.  Moreover, increasing government initiatives to prevent spread of infectious diseases is also expected to boost the market growth in Asia Pacific. For instance, in March 2018, Government of India launched the TB Free India Campaign with an aim to completely eliminate TB by 2025.

Global Infectious Disease Therapeutics Market – Key Players

Major players operating in the global infectious disease therapeutics market include, BioCryst Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceutical, Merck & Co., Inc., Boehringer Ingelheim GmbH, and Novartis International AG.

Major players in the market are focused on product development to expand their product portfolio. For instance, in May 2017, Merck received the U.S. FDA approval for its ISENTRESS HD, a new 1200 mg integrase inhibitor for HIV-1 infected patients. This drug can also be used in combination therapy with other antiretroviral.

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/1658

Global Infectious Disease Therapeutics Market – Taxonomy

The global infectious disease therapeutics market is segmented on the basis of mode of treatment, drug class, disease infection, end user, and region as mentioned below:

By Mode of Treatment

• Drugs
  • Oral Administration
  • Topical
  • Injections
  • Others
• Vaccines

By Drug Class

• Anti-Bacterial
• Anti-Viral
• Anti-Parasite
• Anti-Fungal
• Others

By Disease Indication

• Tuberculosis
• HIV/AIDS
• Influenza
• Hepatitis
• Others

By End User

• Hospital Pharmacy
• Retail Pharmacy
• Others

By Region

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.